Status:
UNKNOWN
Rivaroxaban in Elderly NVAF Patients With or Without Renal Impairment
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
Bayer
Conditions:
Atrial Fibrillation
Rivaroxaban
Eligibility:
All Genders
65+ years
Brief Summary
Study Type and Design Prospective, Observational Study Rivaroxaban in Elderly AF patients with or without renal impairment in Korea This study will investigate effectiveness and safety in elderly pat...
Detailed Description
Study Population Elderly patients with age ≥ 65 years with treatment naïve or treatment-experienced patients who are diagnosed with NVAF Expected number of patient enrollment is about 1200 patients, S...
Eligibility Criteria
Inclusion
- Patients with consent given
- Elderly patients with age 65 ≥ years old
- NVAF patients first time prescription to rivaroxaban or patients who started rivaroxaban treatment within 3 months
Exclusion
- Refusal to participate in this study or to give an informed consent
- Patients with moderate to severe mitral stenosis
- Patients with mechanical valve
- Contraindication from rivaroxaban Korea SmPC
Key Trial Info
Start Date :
September 25 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 30 2022
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT04096547
Start Date
September 25 2019
End Date
August 30 2022
Last Update
October 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710